Preliminary results on the prevalence of male hypogonadism in HIV-infected me

BRIGANTE, Giulia

CARANI, Cesare

DIAZZI, Chiara

G. Orlando

GUARALDI, Giovanni

ROCHIRA, Vincenzo

SANTI, Daniele

SIMONI, Manuela

ZIRILLI, Lucia

English

ORLANDO, Gabriella

Archivio istituzionale della ricerca - Università di Modena e Reggio Emilia

ENDO 2010 Abstract! P2-466 Prevalence and Characterization of Hypogonadismamong Men with Human Immunodeficiency VirusInfection: Preliminary Results. V Rochira1, D Santi1, G Brigante1, L Zirilli1, C Diazzi1, G Orlando1, C Carani1 and G Guaraldi1.1Univ of Modena and Reggio Emilia Modena, Italy.Introduction: Among various comorbidities of Human Immunodeficiency Virus-1 (HIV-1) infection male hypogonadismis very frequent with a prevalence of 19% in patients treated with highly active anti-retroviral therapy (HAART).Literature data are lacking and achieved by studies with less than 300 subjects each.Aim of the study: Prevalence and clinical characterization of hypogonadism among a large number of men withHuman Immunodeficiency Virus Infection.Methods: Endocrinological examination and hormonal screening including serum total testosterone, LH and FSH assayshave been performed in 950 outpatients aged 20-69 years (mean age 45.5 years) at the Metabolic Clinic of Infectiousand Tropical Disease between 2005 and 2009.Results: Mean serum total testosterone was 470.9±205.5 ng/dl. Considering Endocrine Society threshold forhypogonadism diagnosis, 15.7% of our patients was hypogonadic (T<300ng/dl); reffering to LH levels 8% of them washypogonadotropic, 77.2% was normogonadotropic and 14.8% was hypergonadotropic. According to threshold proposedby International Society for the Study of the Aging Male (ISSAM) 23.7% of subjects results hypogonadic (T<346ng/dl) ofwhich 5.8% was hypogonadotropic, 80% normogonadotropic and 14.2% hypergonadotropic.Table 1! Endocrine Society (T<300ng/dl) ISSAM (T<346ng/dl)Percentage of hypogonadism (nhypogonadic/n total)15.7% (149/950) 23.7% (225/950)LH<1.4 mUL/ml 8% (12/149) 5.8% (13/225)1.4<LH<8.9 mUl/ml 77.2% (115/149) 80% (180/225)LH>8.9 mUl/ml 14.8 % (22/149) 14.2% (32/225)Conclusions: Our results demonstrate a prevalence of hypogonadism in HIV patients comparable to older healthysubjects (19.3% of hypogonadism in patients with mean age 58.7 years; Schneider 2009). This study, which is conducedon an elevated number of HIV patients, shows that the prevalence of hypogonadism is higher than in generalpopulation. Normogonadotropism predominance in subjects with hypotestosteronemia suggests also a possibleinvolvement of a pituitary disfunction in the development of hypogonadism.Nothing to Disclose: VR, DS, GB, LZ, CD, GO, CC, GGEndocrine Reviews, Supplement 1, June 2010, 31[3]: S1349AUTHOR INDEXAll faculty/presenters are required to disclose relevant fi nancial interests or confl icts of interest. Disclosure Statements are provided with individual abstracts following each speaker’s name and institution.THE ENDOCRINE SOCIETY / ENDO 2010 ABSTRACTSAUTHOR INDEXReincke, M P2-654Reindollar, RH P1-308Reinehr, T P2-477, P2-708Reiner, B OR35-5, P2-705, P3-687Reinert, RB P3-487Reingold, B P2-513Reinsberg, J P2-390Reis, ACS P1-694Reis, AM P1-331, P3-201Reis, LC P1-217Reis, MC P1-500Reis, MTA P1-186Reisch, N P2-747, P3-23Reiter, K P2-400Reiter, MH P2-481Reitz, E P1-181Reitz, R P2-109Reitz, RE OR22-1Rejnmark, L P1-165Rejon, CA P2-149Remboutsika, E P3-190Ren, R P1-27Ren, S OR38-6, P1-613Renbaum, P P1-690Render, ML OR15-4Rendon, LM P2-307Renne, U P1-415Rensing, KL P2-47Renthal, NE OR-LB6Repaske, DR P3-324Repetto, EM P1-629, P1-631Resch, J P1-73Resl, M P3-434Resmini, E P2-671, P3-637Resnick, JL P3-171Ressio, RA P3-79Rettig, R P2-654Reubi, JC P2-101Reusch, JEB P1-485, P3-137Reuwer, AQ P1-227Revesz, A P1-509Rey, JP P2-273Rey, R P3-340Rey, RA OR35-2Reyes, BAS P1-215Reynaud, R P1-677Reynolds, D P2-726Reynolds, HE P1-621Reynolds, J P1-542Reynolds, JC OR08-6, OR14-2, P3-182Reynolds, RM P3-33Reynoso-Mendoza, R P3-433Rezvani, G P3-693Rhee, EJ P3-187Rhee, SY P1-257Rhee, Y P3-161Rhee, YM OR26-5, P3-166Rhie, YJ P2-65Rhoads, SA OR25-2Rhodes, E P2-550Rhodes, SJ P1-101, P3-694Ribar, TJ P1-460Ribas, V OR01-5Ribeiro, A P2-256Ribeiro, TC P1-652, P3-80, P3-623Ribeiro-dos-Santos, AKC P1-209Ribeiro-Neto, F P3-127Ribeiro-Oliveira, A Jr P1-198, P3-322Ricciardi, L P3-394Ricciato, MP P1-599Ricci, D OR22-2Riccomagno, S P2-729Rice, KA OR38-5Rice, S OR27-3, OR39-5Rich, SS P1-478Rich, TA OR14-1, P3-626, P3-655, P3-656Richard, K P2-158Richard, N P1-156Richard, RJ P1-1Richards, AM P3-234Richards, JS OR28-4, P3-352Richards, ML P3-624Richards, S OR06-1Richardson, E P1-481, P2-258Richardson, KM P3-625Richardson, VM P2-82Richel, DJ P2-47Richer, JR P1-54Richter-Unruh, A OR21-2Rick, FG P1-236Rickard, AJ OR-LB4Rickels, K OR30-3Rickels, MR OR30-3Rickert, EL P3-223Ride, JP P3-28Ridgway, EC OR41-5Ridruejo, C P1-719Rieanrakwong, D P1-329Rieder, MJ P2-675Riedl, M P3-434Riedl, S P3-698Rieger, S P3-44Riepe, FG P3-723Riesgo-Suarez, PA P1-272Rigby, AS P3-584Rigby, E P1-253Rigl, CT P1-542Rijs, KJ OR37-6, P1-178Rimoldi, D P1-719Rink, R P3-723Rio, A P2-330Rios, VM Jr P3-272Rippe, JM P1-495, P2-523Riquelme, EM P2-623Risbridger, GP  P2-37Risek, B P3-65Rissman, EF P2-61Rivarola, MA P2-742, P2-745, P2-746, P2-750Rivas, MA P1-23Rivero-Muller, A P3-343Rivkees, SA P2-595, P3-723Rizos, D OR27-6Robbins, D P3-534Roberge, C P1-420Roberson, M P2-276Roberson, MS P1-108Roberton, A P1-214Roberts, CT P2-162Roberts, G P2-667Roberts, SA OR31-1, P3-336Robertson, DM P2-141, P2-147Robey, P P3-150Robins, DM OR31-4, P1-109, P2-5Robinson, A P2-195Robinson, I P2-315Robinson, IC P2-304Robinson, J P2-383Robinson, LJ P1-725Robitaille, J P1-431, P3-506Robson, HJL P3-18Rocchi, R OR22-2Roch, GJ P1-150Rocha, A P2-58, P2-650Rocha, EPCC P3-495Rocha, G P3-557Rocha, MGM P2-702Rocha, MP P3-387Rocha, MS P3-631Rocha-Filho, JA P1-428Roche, C P2-303Roche, HM P2-398Rochira, V P1-576, P2-466Rochon, PA P2-597Rodd, C P3-278Rodien, P P1-552Rodovalho, GV P1-201Rodrigues, F P1-575Rodrigues, LFAA P3-322Rodrigues, MP P1-500Rodrigues, P P3-306Rodriguez, AL P2-300Rodriguez, L P3-674Rodriguez-Flores, C P2-575Roef, GL P3-165Roelfsema, F OR16-3, P1-260, P2-404, P2-691Roemmler, J P2-352Roganovich, JM P1-277Roger, T P3-607Rogers, B P3-649Rogers, NH P2-507Rogerson, FM OR02-1Roggenbuck, U OR16-6Rogowski, R P3-35Rogozinski, A P2-171, P3-258Rohmer, V P1-552, P3-260Roitman, A P3-539Rojas, P P3-396Rojas-Garcia, PP P1-342, P3-340, P3-341Rojkind, M P3-456Roland, AV P2-275Rolfe, C P1-397Rollene, NL P2-343Rollin, G P3-643Romanholi, DJPC P2-323Romano, L P3-478, P3-480, P3-481, P3-482Romano, MC P3-399Romano, N OR38-1Romano, S P1-576Rome, E P1-371Romeijn, N P1-256Romer, T P2-703Romero, A P2-596Romero, C P2-184Romero, M P2-272Romero-Gutierrez, G P3-507Romijn, JA OR14-6, OR16-3, OR20-2, OR36-5, OR42-4, P1-260, P1-275, P1-649, P2-244, P3-540Romualdi, D P3-394Romundstad, PR S19-3Ronchetti, SA P3-193Ronco, J P2-689Ronconi, V P2-635Rone, MB P3-19Ronin, A P3-419Root, AWR P3-680Root, J P3-704Ropelato, MG OR35-2Ropers, HH P1-308Rosa, TC OR32-3, P3-478, P3-480, P3-482Rosai, J P1-542Rosano, GMC P2-483Rosario, ER P2-478Rose, JC P1-615Rose, SR OR35-6Rose-John, S P1-405Rosemberg, S P3-291, P3-298Rosen, C P3-146Rosen, CJ OR03-1, OR11-2, P2-170, P2-187, P3-119Rosen, CR P2-201Rosenbaum, M P2-717, P3-701, P3-702, P3-703Rosenberg, E P3-175Rosenblatt, S P3-535Rosenbloom, AL P1-659Rosencrantz, MA P2-394Rosenfeld, RG P1-222, P1-659, P1-660, P1-661, P1-664, P2-161Rosenfeld, W P2-717, P3-701, P3-702, P3-703Rosenfi eld, RL P1-704Rosen Mogul, H P3-426Rosenwaks, Z P2-184Rosenzweig, JL P3-715Roseweir, AK OR29-4Rosilio, M P1-665Ross, A P3-573Ross, FP P2-194Ross, GP P1-644Ross, J P1-683, P1-684, P2-336Ross, JL P1-389, P1-674Ross, NA P3-546Ross, RJ P1-221Rossetti, R P1-305Rossi, M P1-543Rossi, MA P2-680Rossi, R P1-543Rossier, BC P3-607Rossier, MF P3-606Rota, CA P2-103Rota, L OR03-6Rotgers, E P3-343Roth, CL P2-477Roth, MY P1-387Roth, R P3-602Rothenberg, R P1-715Rothman, J P3-472Rothwell, SW P2-723Roti, E P1-543Rotman, S P3-607Rotman-Pikielny, P P3-539Rotondi, M P3-595Rotondo, F P2-316Rotter, JI P1-478, P3-504Rottinghaus, GE P3-71Rotwein, P P1-133, P2-140, P3-153, P3-231Rouanet, C P2-58Rouba, H P2-367Roubenoff, R P2-453Roudaut, N P1-261, P1-633Rouleau, J P3-295Rouleau, S OR43-3Roupas, N P3-204Rouse, A P3-701Rouse, DJ OR30-2Rousseau, L P2-224Roussel-Gervais, A P1-616Roux, E P3-138Roux, FX P1-279Roux-Lombard, P P3-606Roveto, S P1-719Rovner, AJ P2-117Rowan, BG P1-47Rowell, J P1-426Roy, S OR29-5Royer, C P2-21Rozentryt, P P1-402Rozhinskaya, LY P3-274Rubeck, KZ P3-246Rubin, B OR21-6, P1-64Rubinek, T OR03-3, P3-45Rubinow, DR P3-199, P3-398Rubio, A P3-191Rudloff, ND P2-570Rudman, S P3-587Rudraiah, M P2-392Ruff, DA OR24-6, P3-511Ruffi lli, I P1-526Ruffi n, M OR16-5Ruggeri, RM P3-103Rui, H P2-289, P2-290Ruiz-Pinio, F P2-272Ruiz-Pino, F P2-269Rumbsby, G P1-323Ruminjo, A P1-610Rundek, T OR26-3 ENDO 2010 Abstracts2View™: http://127.0.0.1:9080/ENDO10/1 di 1 04/11/12 17:52[P2-466] Prevalence and Characterization of Hypogonadism among Men with Human Immunodeficiency VirusInfection: Preliminary Results.V Rochira, D Santi, G Brigante, L Zirilli, C Diazzi, G Orlando, C Carani, G Guaraldi. Univ of Modena and ReggioEmilia, Modena, ItalyIntroduction: Among various comorbidities of Human Immunodeficiency Virus-1 (HIV-1) infection male hypogonadismis very frequent with a prevalence of 19% in patients treated with highly active anti-retroviral therapy (HAART).Literature data are lacking and achieved by studies with less than 300 subjects each.Aim of the study: Prevalence and clinical characterization of hypogonadism among a large number of men withHuman Immunodeficiency Virus Infection.Methods: Endocrinological examination and hormonal screening including serum total testosterone, LH and FSHassays have been performed in 950 outpatients aged 20-69 years (mean age 45.5 years) at the Metabolic Clinic ofInfectious and Tropical Disease between 2005 and 2009.Results: Mean serum total testosterone was 470.9±205.5 ng/dl. Considering Endocrine Society threshold forhypogonadism diagnosis, 15.7% of our patients was hypogonadic (T<300ng/dl); reffering to LH levels 8% of them washypogonadotropic, 77.2% was normogonadotropic and 14.8% was hypergonadotropic. According to thresholdproposed by International Society for the Study of the Aging Male (ISSAM) 23.7% of subjects results hypogonadic(T<346ng/dl) of which 5.8% was hypogonadotropic, 80% normogonadotropic and 14.2% hypergonadotropic.Table 1 Endocrine Society (T<300ng/dl) ISSAM (T<346ng/dl)Percentage of hypogonadism (n hypogonadic/n total) 15.7% (149/950) 23.7% (225/950)LH<1.4 mUL/ml 8% (12/149) 5.8% (13/225)1.4<8.9 mUl/ml 77.2% (115/149) 80% (180/225)LH>8.9 mUl/ml 14.8 % (22/149) 14.2% (32/225)Conclusions: Our results demonstrate a prevalence of hypogonadism in HIV patients comparable to older healthysubjects (19.3% of hypogonadism in patients with mean age 58.7 years; Schneider 2009). This study, which isconduced on an elevated number of HIV patients, shows that the prevalence of hypogonadism is higher than ingeneral population. Normogonadotropism predominance in subjects with hypotestosteronemia suggests also apossible involvement of a pituitary disfunction in the development of hypogonadism.Nothing to Disclose: VR, DS, GB, LZ, CD, GO, CC, GGDate: Sunday, June 20, 2010Session Info: POSTER SESSION: CLINICAL - Pathophysiology, Diagnosis & Treatment of Male Hypogonadism (1:30PM-3:30 PM)Presentation Time: 01:30 PMRoom: Halls D-G Embargo PolicyUnless otherwise noted, all abstracts presented at ENDO are embargoed until the date and time of presentation.Abstracts presented at a news conference are embargoed until the date and time of the news conference. TheEndocrine Society reserves the right to lift the embargo on specific abstracts that are selected for promotion prior to orduring ENDO.Disclaimer StatementThe information presented at ENDO news conferences and within the Research Summaries Book represents theopinion of the presenters and authors and is not necessarily the view of The Endocrine Society. The EndocrineSociety makes no representation as to the truth or warranty, accuracy, or originality of the information presented.For additional information, please contact The Endocrine Society’s Public Affairs Department at 301-941-0240 orariskind@endo-society.org. Abstract ENDO10L_P2-466: Contact View http://127.0.0.1:9080/ENDO10/view.y?nu=ENDO10L_P2-4661 di 2 04/11/12 17:54